FYERS
Home
/
Stocks
/
Results
/
Mankind Pharma Results

Mankind Pharma Results

Financial overview

CAGR%
Sales
Profits
Returns
ROE
10Y5Y3YTTM
14%18%18%17%
13%9%14%-3%
--12%-4%
23%20%18%13%

Peer Comparison

Symbol
SUNPHARMA
DIVISLAB
TORNTPHARM
ZYDUSLIFE
CIPLA
LAURUSLABS
MANKIND
DRREDDY
AUROPHARMA
LUPIN
PriceM.Cap (₹)PE RatioEPS (₹)EV/EBITDAAnnual PAT
1,849.9₹447476 Cr3712.0762.82₹11479 Cr
9,602₹254764 Cr87.134.04128.41₹2568 Cr
4,928.5₹189423 Cr86.8516.7297.06₹2163 Cr
1,180.3₹116658 Cr25.859.4262.53₹5040 Cr
1,399₹111484 Cr33.089.7757.87₹3879 Cr
2,026.2₹109943 Cr100.556.829.25₹889 Cr
2,500₹101712 Cr49.7913.7571.08₹1913 Cr
1,200.4₹101005 Cr31.355.3263.99₹4196 Cr
1,716₹99253 Cr26.7317.9596.84₹3505 Cr
2,100.7₹96031 Cr17.3730.95154.35₹5333 Cr

Profit & Loss

Consolidated
Standalone
Quarterly
Yearly
₹
%

Balance Sheet

Consolidated
Standalone
₹
%
Name
Equity And Liabilities
Share Capital
Share Warrants & Outstandings
Total Reserves
Reserve excluding Revaluation Reserve
Shareholder's Funds
Minority Interest
Secured Loans
Unsecured Loans
Deferred Tax Assets / Liabilities
Other Long Term Liabilities
Long Term Provisions
Total Non-Current Liabilities
Current Liabilities
Trade Payables
Other Current Liabilities
Short Term Borrowings
Short Term Provisions
Total Current Liabilities
Total Liabilities
Contingent Liabilities
Total Debt
Assets
Gross Block
Less Accumulated Depreciation
Less Impairment of Assets
Net Block
Capital Work in Progress
Non Current Investments
Long Term Investment
Long Term Loans & Advances
Other Non Current Assets
Total Non-Current Assets
Current Assets Loans & Advances
Currents Investments
Inventories
Sundry Debtors
Cash and Bank
Other Current Assets
Short Term Loans and Advances
Total Current Assets
Net Current Assets (Including Current Investments)
Total Assets
Book Value
Adjusted Book Value
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
————————————
₹41 Cr₹41 Cr₹40 Cr₹40 Cr₹40 Cr₹40 Cr₹40 Cr₹40 Cr₹40 Cr₹20 Cr₹20 Cr₹20 Cr
₹48 Cr₹44 Cr₹23 Cr₹6 L₹0₹0₹0₹0₹0₹0₹0₹0
₹16211 Cr₹14248 Cr₹9300 Cr₹7395 Cr₹6115 Cr₹4682 Cr₹3445 Cr₹2783 Cr₹2841 Cr₹2907 Cr₹2237 Cr₹2035 Cr
₹16211 Cr₹14248 Cr₹9300 Cr₹7395 Cr₹6115 Cr₹4682 Cr₹3445 Cr₹2783 Cr₹2841 Cr₹2907 Cr₹2237 Cr₹2035 Cr
₹16300 Cr₹14332 Cr₹9363 Cr₹7435 Cr₹6155 Cr₹4722 Cr₹3485 Cr₹2823 Cr₹2881 Cr₹2927 Cr₹2257 Cr₹2055 Cr
₹261 Cr₹236 Cr₹213 Cr₹188 Cr₹161 Cr₹141 Cr₹186 Cr₹159 Cr₹134 Cr₹98 Cr₹29 Cr₹16 Cr
₹2483 Cr₹5078 Cr₹25 Cr₹23 Cr₹49 Cr₹57 Cr₹58 Cr₹25 Cr₹3 Cr₹1 Cr₹10 L₹2 L
₹339 Cr₹448 Cr₹0₹0₹25 L₹25 L₹0₹0₹34 L₹1 Cr₹2 Cr₹0
₹1515 Cr₹1705 Cr₹9 Cr₹48 Cr₹16 Cr-₹36 Cr-₹40 Cr-₹7 Cr₹2 Cr₹20 Cr₹14 Cr-₹72 L
₹101 Cr₹34 Cr₹31 Cr₹31 Cr₹23 Cr₹13 Cr₹22 Cr₹14 Cr₹8 Cr₹6 Cr₹47 L₹16 Cr
₹249 Cr₹155 Cr₹123 Cr₹98 Cr₹80 Cr₹72 Cr₹63 Cr₹45 Cr₹36 Cr₹25 Cr₹18 Cr₹13 Cr
₹4687 Cr₹7420 Cr₹187 Cr₹199 Cr₹169 Cr₹107 Cr₹103 Cr₹78 Cr₹49 Cr₹53 Cr₹34 Cr₹28 Cr
————————————
₹1341 Cr₹1133 Cr₹777 Cr₹1008 Cr₹1076 Cr₹667 Cr₹745 Cr₹562 Cr₹649 Cr₹492 Cr₹419 Cr₹380 Cr
₹3702 Cr₹1335 Cr₹756 Cr₹386 Cr₹473 Cr₹283 Cr₹180 Cr₹117 Cr₹162 Cr₹140 Cr₹101 Cr₹52 Cr
₹639 Cr₹2513 Cr₹151 Cr₹115 Cr₹795 Cr₹158 Cr₹44 Cr₹241 Cr₹404 Cr₹10 Cr₹0₹0
₹825 Cr₹682 Cr₹436 Cr₹354 Cr₹280 Cr₹245 Cr₹281 Cr₹104 Cr₹81 Cr₹21 Cr₹8 Cr₹1 Cr
₹6507 Cr₹5664 Cr₹2120 Cr₹1863 Cr₹2623 Cr₹1353 Cr₹1251 Cr₹1024 Cr₹1296 Cr₹663 Cr₹528 Cr₹433 Cr
₹27755 Cr₹27652 Cr₹11883 Cr₹9686 Cr₹9108 Cr₹6324 Cr₹5025 Cr₹4084 Cr₹4360 Cr₹3741 Cr₹2848 Cr₹2532 Cr
₹925 Cr₹1019 Cr₹89 Cr₹48 Cr₹83 Cr₹35 Cr₹242 Cr₹361 Cr₹16 Cr₹31 Cr₹21 Cr₹24 Cr
₹6022 Cr₹8300 Cr₹196 Cr₹163 Cr₹868 Cr₹235 Cr₹128 Cr₹270 Cr₹407 Cr₹13 Cr₹2 Cr₹2 L
————————————
₹21377 Cr₹20917 Cr₹5910 Cr₹5233 Cr₹4247 Cr₹2160 Cr₹1988 Cr₹1681 Cr₹1230 Cr₹915 Cr₹489 Cr₹403 Cr
₹2756 Cr₹1912 Cr₹1370 Cr₹988 Cr₹664 Cr₹501 Cr₹373 Cr₹282 Cr₹216 Cr₹122 Cr₹42 Cr₹126 Cr
₹0₹0₹0₹0₹0₹0₹21 Cr₹0₹0₹0₹0₹0
₹18620 Cr₹19005 Cr₹4540 Cr₹4245 Cr₹3583 Cr₹1659 Cr₹1594 Cr₹1399 Cr₹1014 Cr₹793 Cr₹447 Cr₹277 Cr
₹655 Cr₹306 Cr₹207 Cr₹493 Cr₹670 Cr₹372 Cr₹313 Cr₹327 Cr₹482 Cr₹302 Cr₹139 Cr₹44 Cr
₹448 Cr₹351 Cr₹310 Cr₹271 Cr₹235 Cr₹206 Cr₹164 Cr₹216 Cr₹139 Cr₹101 Cr₹54 Cr₹42 Cr
₹448 Cr₹351 Cr₹310 Cr₹271 Cr₹235 Cr₹206 Cr₹164 Cr₹216 Cr₹139 Cr₹101 Cr₹54 Cr₹42 Cr
₹555 Cr₹293 Cr₹164 Cr₹188 Cr₹164 Cr₹158 Cr₹106 Cr₹118 Cr₹77 Cr₹260 Cr₹336 Cr₹270 Cr
₹50 Cr₹189 Cr₹14 Cr₹99 Cr₹13 Cr₹17 Cr₹16 Cr₹14 Cr₹9 Cr₹9 Cr₹7 Cr₹42 Cr
₹20801 Cr₹20663 Cr₹5315 Cr₹5358 Cr₹4702 Cr₹2417 Cr₹2203 Cr₹2085 Cr₹1787 Cr₹1672 Cr₹1142 Cr₹859 Cr
————————————
₹1537 Cr₹1691 Cr₹2258 Cr₹1075 Cr₹874 Cr₹1306 Cr₹665 Cr₹543 Cr₹650 Cr₹848 Cr₹655 Cr₹737 Cr
₹2144 Cr₹2094 Cr₹1553 Cr₹1498 Cr₹1760 Cr₹1184 Cr₹899 Cr₹821 Cr₹789 Cr₹789 Cr₹619 Cr₹596 Cr
₹1730 Cr₹1538 Cr₹848 Cr₹576 Cr₹388 Cr₹331 Cr₹531 Cr₹220 Cr₹297 Cr₹166 Cr₹193 Cr₹197 Cr
₹483 Cr₹555 Cr₹708 Cr₹453 Cr₹406 Cr₹701 Cr₹420 Cr₹141 Cr₹139 Cr₹146 Cr₹90 Cr₹39 Cr
₹101 Cr₹97 Cr₹104 Cr₹64 Cr₹171 Cr₹83 Cr₹10 Cr₹8 Cr₹469 Cr₹31 Cr₹86 Cr₹62 Cr
₹957 Cr₹1011 Cr₹1093 Cr₹657 Cr₹804 Cr₹276 Cr₹294 Cr₹209 Cr₹230 Cr₹89 Cr₹64 Cr₹42 Cr
₹6952 Cr₹6986 Cr₹6566 Cr₹4325 Cr₹4404 Cr₹3880 Cr₹2820 Cr₹1943 Cr₹2574 Cr₹2069 Cr₹1707 Cr₹1673 Cr
₹444 Cr₹1322 Cr₹4446 Cr₹2461 Cr₹1780 Cr₹2526 Cr₹1569 Cr₹919 Cr₹1277 Cr₹1406 Cr₹1179 Cr₹1240 Cr
₹27755 Cr₹27652 Cr₹11883 Cr₹9686 Cr₹9108 Cr₹6324 Cr₹5025 Cr₹4084 Cr₹4360 Cr₹3741 Cr₹2848 Cr₹2532 Cr
₹394₹346₹233₹186₹154₹118₹87₹70₹72₹1,461₹1,127₹1,026
₹394₹346₹233₹186₹154₹118₹87₹70₹72₹73₹56₹51

Cash Flow

Consolidated
Standalone
₹
%
Name
Profit Before Tax
Adjustment
Changes In working Capital
Cash Flow after changes in Working Capital
Cash Flow from Operating Activities
Cash Flow from Investing Activities
Cash Flow from Financing Activitie
Net Cash Inflow / Outflow
Opening Cash & Cash Equivalents
Cash & Cash Equivalent on Amalgamation / Take over / Merger
Cash & Cash Equivalent of Subsidiaries under liquidations
Effect of Foreign Exchange Fluctuations
Closing Cash & Cash Equivalent
Mar 2026Mar 2025Mar 2024Mar 2023Mar 2022Mar 2021Mar 2020Mar 2019Mar 2018Mar 2017Mar 2016Mar 2015
₹2333 Cr₹2525 Cr₹2399 Cr₹1671 Cr₹1975 Cr₹1692 Cr₹1438 Cr₹865 Cr₹995 Cr₹906 Cr₹784 Cr₹621 Cr
₹1277 Cr₹602 Cr₹212 Cr₹298 Cr₹31 Cr-₹6 Cr₹105 Cr₹87 Cr₹109 Cr₹20 Cr-₹19 Cr₹13 Cr
₹105 Cr-₹146 Cr-₹18 Cr₹167 Cr-₹586 Cr-₹95 Cr-₹140 Cr-₹10 Cr-₹141 Cr-₹12 Cr₹17 Cr-₹121 Cr
₹3714 Cr₹2980 Cr₹2594 Cr₹2136 Cr₹1419 Cr₹1591 Cr₹1403 Cr₹942 Cr₹963 Cr₹914 Cr₹782 Cr₹512 Cr
₹3121 Cr₹2413 Cr₹2152 Cr₹1813 Cr₹920 Cr₹1137 Cr₹1072 Cr₹600 Cr₹639 Cr₹628 Cr₹537 Cr₹280 Cr
-₹196 Cr-₹12683 Cr-₹2082 Cr-₹1054 Cr-₹1369 Cr-₹1222 Cr-₹439 Cr-₹444 Cr-₹505 Cr-₹625 Cr-₹152 Cr-₹348 Cr
-₹2953 Cr₹10233 Cr₹5 Cr-₹740 Cr₹605 Cr-₹8 Cr-₹527 Cr-₹175 Cr-₹89 Cr₹2 Cr-₹361 Cr₹9 Cr
-₹28 Cr-₹37 Cr₹76 Cr₹19 Cr₹155 Cr-₹93 Cr₹106 Cr-₹19 Cr₹46 Cr₹5 Cr₹25 Cr-₹59 Cr
₹404 Cr₹382 Cr₹305 Cr₹283 Cr₹127 Cr₹220 Cr₹116 Cr₹136 Cr₹89 Cr₹82 Cr₹53 Cr₹98 Cr
₹0-₹9 Cr₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹0₹67 Cr₹0₹0₹0₹0₹0₹0₹0₹0₹0₹0
₹16 Cr₹1 Cr₹1 Cr₹2 Cr₹48 L₹38 L₹4 Cr-₹2 L₹3 L-₹6 L-₹4 L₹0
₹392 Cr₹404 Cr₹382 Cr₹305 Cr₹283 Cr₹127 Cr₹226 Cr₹116 Cr₹135 Cr₹87 Cr₹78 Cr₹39 Cr

Fundamental Ratios

Consolidated
Standalone

Share Price Live Stats

Open (₹)2,442.60
Volume (₹)4.47 L
High (₹)2,504.30
Upper Circuit2,553.70
Low (₹)2,442.60
Lower Circuit2,405.10
Prev Close2,465.00
52W High (₹)2,642.00
Price2,500.00
52W Low (₹)1,909.70

Share Market Cap & Key Ratios Overview

M.Cap (₹)101712.00 Cr
Div. Yield (%)0.04
PE Ratio49.79
Debt to Equity0.37
Price to Book5.09
Book Value393.72
EPS (TTM)49.45
Face Value1.00
ROE (%)12.69

Stock Analysis (SWOT)

StrengthsWeaknessesOpportunitiesThreats
1. Premium insight available after login
2. Sign in to view full SWOT analysis
3. Unlock strengths, weaknesses, opportunities & threats
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

QVT

Quality
0/100-
Valuation
0/100-
Technical
0/100-
Sign in to view
Open a free Demat account in minutes to start investing and screening .
LoginSign Up

Peer Stocks

1 week
1 month
1 year
Name
SUNPHARMANSE
DIVISLABNSE
TORNTPHARMNSE
ZYDUSLIFENSE
CIPLANSE
LAURUSLABSNSE
MANKINDNSE
DRREDDYNSE
AUROPHARMANSE
LUPINNSE
LTP
1W Low
1W High
Market cap (₹)
1849.9+12.6 (0.69%)
1832.20
1891.50
4,47,476Cr
9602+227 (2.42%)
9312.50
9740
2,54,764Cr
4928.5+88.5 (1.83%)
4848.50
5010
1,89,423Cr
1180.3+20.3 (1.75%)
1152.10
1190.60
1,16,658Cr
1399+4.5 (0.32%)
1364.50
1419
1,11,484Cr
2026.2+72.2 (3.69%)
1963.80
2055.30
1,09,943Cr
2500+199.3 (8.66%)
2303
2504.30
1,01,712Cr
1200.4+15.4 (1.30%)
1185
1222
1,01,005Cr
1716-18 (-1.04%)
1689.30
1740
99,253Cr
2100.7+17.7 (0.85%)
2080
2135
96,031Cr

Mankind Pharma Ltd Annual Results Key Takeaways

Operating profit (before other income, interest and exceptional items) was ₹1101.19Cr; with other income of ₹45Cr, profit before interest and tax came to ₹875.49Cr. Interest expense was ₹109.98Cr; PBT before exceptional items stood at ₹765.51Cr. Cost mix (full year): raw materials ₹4016Cr; employee cost ₹3183.9Cr; depreciation ₹225.7Cr; other expenses ₹2974.4Cr. Basis: consolidated annual results.

Mankind Pharma Ltd Quaterly Results Key Takeaways

Mankind Pharma Ltd reported ₹4030.59Cr total income from operations in Jun 2026, softer than ₹3442.93Cr in Mar 2026 but higher than ₹3570.35Cr in Jun 2025. Operating profit (before other income, interest and exceptional items) was ₹1101.19Cr; with other income of ₹45Cr, profit before interest and tax came to ₹875.49Cr. Interest expense was ₹109.98Cr, taking profit before tax to ₹765.51Cr. After tax of ₹195.36Cr, profit after tax stood at ₹570.15Cr (vs ₹556.43Cr in Mar 2026 and ₹441.45Cr in Jun 2025).